- Conditions
- Urticaria, Angioedema, Hives, Swelling
- Interventions
- High Dose Vitamin D3, Low Dose Vitamin D3
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 3,130
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2030
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Anaheim, California + 49 more
- Conditions
- HIV Infections, HIV Seronegativity, Atherosclerosis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 10
- States / cities
- Harbor City, California • Los Angeles, California • San Diego, California + 5 more
- Conditions
- ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
- Interventions
- FT839
- Biological
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Neoplasms
- Interventions
- GSK525762
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • New York, New York + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Guided Lesion Biopsies, Standard Lesion Biopsies
- Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib, Dexamethasone, Dexamethasone Sodium Phosphate, Echocardiography, Lenalidomide, Navtemadlin
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 7
- States / cities
- Sacramento, California • Aurora, Colorado • New York, New York + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib (Velcade)
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Rhinitis, Urticaria
- Interventions
- levocetirizine or placebo
- Drug
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Tumor, Cancer, Pain, Malignant Solid Tumor, Unresectable Malignant Neoplasm, Hematologic Malignancy, Multiple Myeloma, Lymphoma, Neoplasm Metastasis
- Interventions
- Sodium Bicarbonate
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vorinostat
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
- Biological · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
- Interventions
- LP-168
- Drug
- Lead sponsor
- Newave Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Durham, North Carolina • Cincinnati, Ohio • Columbus, Ohio + 1 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Solid Tumors, Multiple Myeloma
- Interventions
- ACE-041
- Biological
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Durham, North Carolina • Nashville, Tennessee + 1 more
- Conditions
- Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
- Interventions
- Fluzone High Dose Vaccine, Standard of care/Placebo
- Biological
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Myeloma
- Interventions
- Alnuctamab, Pomalidomide, Daratumumab, Elotuzumab, Carfilzomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 19 more
- Conditions
- Inflammation, Pathologic Processes
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Spartanburg, South Carolina • Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- 64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT
- Drug · Device · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hereditary Angioedema, HAE
- Interventions
- BCX4161, Placebo
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Granada Hills, California + 21 more
- Conditions
- Includes: Hereditary Angioedema
- Interventions
- Berinert® (C1 Esterase Inhibitor)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Not listed
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 31 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition
- Interventions
- tetradecanoylphorbol acetate
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey